CONFIDENTIAL

Comprehensive BRACAnalysis®
BRCA1 and *BRCA2* Analysis Result

PHYSICIAN	SPECIMEN	PATIENT
John Smith, MD **Comprehensive Medical Center** **1100 Grand Ave** **Away, GA 12345**	Specimen: **Blood** Draw date: **Aug 01, 2010** Accession date: **Aug 02, 2010** Report Date: **Jun 22, 2011**	Name: **Doe, Jane** Date of Birth: **April 1, 1492** Patient ID: **000000** Gender: **Female** Accession #: **00000000-BLD** Requisition #: **000000**

Test Results and Interpretation

GENETIC VARIANT OF UNCERTAIN SIGNIFICANCE

Test Performed:	Result:	Interpretation:
BRCA1 sequencing	No Mutation Detected	No Mutation Detected
5-site rearrangement panel	No Mutation Detected	No Mutation Detected
BRCA2 sequencing	R18W (281A>G)	Uncertain Significance

It is our understanding that this patient was identified for testing due to a personal or family history suggestive of hereditary breast and ovarian cancer. Analysis consists of sequencing of all translated exons and immediately adjacent intronic regions of the BRCA1 and BRCA2 genes and a test for five specific BRCA1 rearrangements. There are additional large genomic rearrangements in BRCA1 and in BRCA2, which are not detected by this test, but can be identified with the BRACAnalysis Rearrangement Test (BART). The classification and interpretation of all variants identified in this assay reflects the current state of scientific understanding at the time this report was issued. In some instances, the classification and interpretation of such variants may change as new scientific information becomes available.

The *BRCA2* variant R18W results in the substitution of tryptophan for arginine at amino acid position 18 of the *BRCA2* protein. Variants of this type may or may not affect the function of the protein encoded by the gene in which it is found. Therefore, the contribution of this variant to the relative risk of breast, ovarian, pancreatic, or other cancers cannot be established solely from this analysis.

Please contact Myriad Professional Support at 1-800-469-7423 to discuss any questions regarding this result.

Director Name Here
Qualifications Here

Director Name Here
Qualifications Here

These test results should only be used in conjunction with the patient's clinical history and any previous analysis of appropriate family members. It is strongly recommended that these test results be communicated to the patient in a setting that includes appropriate counseling. The accompanying Technical Specifications summary describes the analysis, method, performance characteristics, nomenclature, and interpretive criteria of this test. This test may be considered investigational by some states. This test and its performance characteristics were determined by Myriad Genetic Laboratories. It has not been reviewed by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.